nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—FKBP1A—esophageal cancer	0.774	1	CbGaD
Everolimus—MTOR—neck—esophageal cancer	0.00282	0.123	CbGeAlD
Everolimus—FKBP1A—neck—esophageal cancer	0.00254	0.111	CbGeAlD
Everolimus—Pimecrolimus—FKBP1A—esophageal cancer	0.00242	0.333	CrCbGaD
Everolimus—MTOR—epithelium—esophageal cancer	0.00192	0.084	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—esophageal cancer	0.00185	0.081	CbGeAlD
Everolimus—FKBP1A—epithelium—esophageal cancer	0.00173	0.0756	CbGeAlD
Everolimus—FKBP1A—bronchus—esophageal cancer	0.0017	0.0744	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—esophageal cancer	0.00166	0.0728	CbGeAlD
Everolimus—Temsirolimus—FKBP1A—esophageal cancer	0.00163	0.225	CrCbGaD
Everolimus—FKBP1A—trachea—esophageal cancer	0.00153	0.0668	CbGeAlD
Everolimus—MTOR—digestive system—esophageal cancer	0.00146	0.0639	CbGeAlD
Everolimus—Tacrolimus—FKBP1A—esophageal cancer	0.00144	0.198	CrCbGaD
Everolimus—Sirolimus—FKBP1A—esophageal cancer	0.00144	0.198	CrCbGaD
Everolimus—FKBP1A—digestive system—esophageal cancer	0.00131	0.0575	CbGeAlD
Everolimus—MTOR—lung—esophageal cancer	0.00122	0.0534	CbGeAlD
Everolimus—FKBP1A—lung—esophageal cancer	0.0011	0.048	CbGeAlD
Everolimus—MTOR—lymph node—esophageal cancer	0.000835	0.0365	CbGeAlD
Everolimus—FKBP1A—lymph node—esophageal cancer	0.000751	0.0328	CbGeAlD
Everolimus—CYP3A4—digestive system—esophageal cancer	0.000429	0.0188	CbGeAlD
Everolimus—Neoplasm—Methotrexate—esophageal cancer	0.000168	0.00143	CcSEcCtD
Everolimus—Mouth ulceration—Methotrexate—esophageal cancer	0.000168	0.00143	CcSEcCtD
Everolimus—Urinary tract disorder—Cisplatin—esophageal cancer	0.000168	0.00143	CcSEcCtD
Everolimus—Liver function test abnormal—Capecitabine—esophageal cancer	0.000167	0.00142	CcSEcCtD
Everolimus—Connective tissue disorder—Cisplatin—esophageal cancer	0.000167	0.00142	CcSEcCtD
Everolimus—Urethral disorder—Cisplatin—esophageal cancer	0.000166	0.00142	CcSEcCtD
Everolimus—Dry skin—Capecitabine—esophageal cancer	0.000166	0.00141	CcSEcCtD
Everolimus—Abdominal pain upper—Capecitabine—esophageal cancer	0.000165	0.00141	CcSEcCtD
Everolimus—Pulmonary oedema—Methotrexate—esophageal cancer	0.000165	0.00141	CcSEcCtD
Everolimus—Hypokalaemia—Capecitabine—esophageal cancer	0.000165	0.0014	CcSEcCtD
Everolimus—Breast disorder—Capecitabine—esophageal cancer	0.000164	0.00139	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000163	0.00139	CcSEcCtD
Everolimus—Nasopharyngitis—Capecitabine—esophageal cancer	0.000162	0.00138	CcSEcCtD
Everolimus—Sepsis—Methotrexate—esophageal cancer	0.000161	0.00137	CcSEcCtD
Everolimus—Gastritis—Capecitabine—esophageal cancer	0.00016	0.00136	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00016	0.00136	CcSEcCtD
Everolimus—Muscular weakness—Capecitabine—esophageal cancer	0.00016	0.00136	CcSEcCtD
Everolimus—Eye disorder—Cisplatin—esophageal cancer	0.000159	0.00135	CcSEcCtD
Everolimus—Lymphadenopathy—Methotrexate—esophageal cancer	0.000158	0.00134	CcSEcCtD
Everolimus—Flushing—Cisplatin—esophageal cancer	0.000158	0.00134	CcSEcCtD
Everolimus—Cardiac disorder—Cisplatin—esophageal cancer	0.000158	0.00134	CcSEcCtD
Everolimus—Abdominal distension—Capecitabine—esophageal cancer	0.000157	0.00134	CcSEcCtD
Everolimus—Influenza—Capecitabine—esophageal cancer	0.000156	0.00133	CcSEcCtD
Everolimus—Dysphagia—Capecitabine—esophageal cancer	0.000156	0.00133	CcSEcCtD
Everolimus—Diabetes mellitus—Methotrexate—esophageal cancer	0.000155	0.00132	CcSEcCtD
Everolimus—Bronchospasm—Capecitabine—esophageal cancer	0.000154	0.00131	CcSEcCtD
Everolimus—Polyuria—Methotrexate—esophageal cancer	0.000153	0.00131	CcSEcCtD
Everolimus—Immune system disorder—Cisplatin—esophageal cancer	0.000153	0.00131	CcSEcCtD
Everolimus—Mediastinal disorder—Cisplatin—esophageal cancer	0.000153	0.0013	CcSEcCtD
Everolimus—Angina pectoris—Capecitabine—esophageal cancer	0.000152	0.0013	CcSEcCtD
Everolimus—Bronchitis—Capecitabine—esophageal cancer	0.00015	0.00128	CcSEcCtD
Everolimus—Alopecia—Cisplatin—esophageal cancer	0.00015	0.00128	CcSEcCtD
Everolimus—Hepatic failure—Methotrexate—esophageal cancer	0.00015	0.00128	CcSEcCtD
Everolimus—Pancytopenia—Capecitabine—esophageal cancer	0.000149	0.00127	CcSEcCtD
Everolimus—Erythema—Cisplatin—esophageal cancer	0.000148	0.00126	CcSEcCtD
Everolimus—Malnutrition—Cisplatin—esophageal cancer	0.000148	0.00126	CcSEcCtD
Everolimus—Dysuria—Capecitabine—esophageal cancer	0.000146	0.00125	CcSEcCtD
Everolimus—Neutropenia—Capecitabine—esophageal cancer	0.000146	0.00125	CcSEcCtD
Everolimus—Renal failure acute—Methotrexate—esophageal cancer	0.000146	0.00124	CcSEcCtD
Everolimus—Flatulence—Cisplatin—esophageal cancer	0.000146	0.00124	CcSEcCtD
Everolimus—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000145	0.00124	CcSEcCtD
Everolimus—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000143	0.00122	CcSEcCtD
Everolimus—Muscle spasms—Cisplatin—esophageal cancer	0.000142	0.00121	CcSEcCtD
Everolimus—Weight decreased—Capecitabine—esophageal cancer	0.000141	0.00121	CcSEcCtD
Everolimus—Hyperglycaemia—Capecitabine—esophageal cancer	0.000141	0.0012	CcSEcCtD
Everolimus—Pneumonia—Capecitabine—esophageal cancer	0.00014	0.00119	CcSEcCtD
Everolimus—Infestation—Capecitabine—esophageal cancer	0.000139	0.00119	CcSEcCtD
Everolimus—Infestation NOS—Capecitabine—esophageal cancer	0.000139	0.00119	CcSEcCtD
Everolimus—Vision blurred—Cisplatin—esophageal cancer	0.000139	0.00119	CcSEcCtD
Everolimus—Tremor—Cisplatin—esophageal cancer	0.000138	0.00118	CcSEcCtD
Everolimus—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000137	0.00117	CcSEcCtD
Everolimus—Lethargy—Methotrexate—esophageal cancer	0.000137	0.00117	CcSEcCtD
Everolimus—Ill-defined disorder—Cisplatin—esophageal cancer	0.000137	0.00117	CcSEcCtD
Everolimus—Renal failure—Capecitabine—esophageal cancer	0.000137	0.00117	CcSEcCtD
Everolimus—Myocardial infarction—Capecitabine—esophageal cancer	0.000137	0.00116	CcSEcCtD
Everolimus—Anaemia—Cisplatin—esophageal cancer	0.000137	0.00116	CcSEcCtD
Everolimus—Jaundice—Capecitabine—esophageal cancer	0.000136	0.00116	CcSEcCtD
Everolimus—Stomatitis—Capecitabine—esophageal cancer	0.000136	0.00116	CcSEcCtD
Everolimus—Urinary tract infection—Capecitabine—esophageal cancer	0.000136	0.00115	CcSEcCtD
Everolimus—Conjunctivitis—Capecitabine—esophageal cancer	0.000136	0.00115	CcSEcCtD
Everolimus—Malaise—Cisplatin—esophageal cancer	0.000133	0.00114	CcSEcCtD
Everolimus—Haematuria—Capecitabine—esophageal cancer	0.000133	0.00113	CcSEcCtD
Everolimus—Leukopenia—Cisplatin—esophageal cancer	0.000132	0.00113	CcSEcCtD
Everolimus—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000132	0.00112	CcSEcCtD
Everolimus—Epistaxis—Capecitabine—esophageal cancer	0.000132	0.00112	CcSEcCtD
Everolimus—Irritability—Methotrexate—esophageal cancer	0.000129	0.0011	CcSEcCtD
Everolimus—Convulsion—Cisplatin—esophageal cancer	0.000128	0.00109	CcSEcCtD
Everolimus—Myalgia—Cisplatin—esophageal cancer	0.000126	0.00107	CcSEcCtD
Everolimus—Haemoglobin—Capecitabine—esophageal cancer	0.000126	0.00107	CcSEcCtD
Everolimus—Rhinitis—Capecitabine—esophageal cancer	0.000125	0.00107	CcSEcCtD
Everolimus—Anxiety—Cisplatin—esophageal cancer	0.000125	0.00107	CcSEcCtD
Everolimus—Haemorrhage—Capecitabine—esophageal cancer	0.000125	0.00107	CcSEcCtD
Everolimus—Hepatitis—Capecitabine—esophageal cancer	0.000125	0.00107	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000125	0.00106	CcSEcCtD
Everolimus—Hypoaesthesia—Capecitabine—esophageal cancer	0.000125	0.00106	CcSEcCtD
Everolimus—Liver function test abnormal—Methotrexate—esophageal cancer	0.000124	0.00106	CcSEcCtD
Everolimus—Discomfort—Cisplatin—esophageal cancer	0.000124	0.00106	CcSEcCtD
Everolimus—Pharyngitis—Capecitabine—esophageal cancer	0.000124	0.00106	CcSEcCtD
Everolimus—Urinary tract disorder—Capecitabine—esophageal cancer	0.000124	0.00105	CcSEcCtD
Everolimus—Oedema peripheral—Capecitabine—esophageal cancer	0.000123	0.00105	CcSEcCtD
Everolimus—Connective tissue disorder—Capecitabine—esophageal cancer	0.000123	0.00105	CcSEcCtD
Everolimus—Urethral disorder—Capecitabine—esophageal cancer	0.000123	0.00105	CcSEcCtD
Everolimus—Breast disorder—Methotrexate—esophageal cancer	0.000122	0.00104	CcSEcCtD
Everolimus—Oedema—Cisplatin—esophageal cancer	0.000121	0.00103	CcSEcCtD
Everolimus—Temsirolimus—ABCB1—esophageal cancer	0.00012	0.0166	CrCbGaD
Everolimus—Infection—Cisplatin—esophageal cancer	0.00012	0.00102	CcSEcCtD
Everolimus—Nervous system disorder—Cisplatin—esophageal cancer	0.000118	0.00101	CcSEcCtD
Everolimus—Thrombocytopenia—Cisplatin—esophageal cancer	0.000118	0.00101	CcSEcCtD
Everolimus—Tachycardia—Cisplatin—esophageal cancer	0.000118	0.001	CcSEcCtD
Everolimus—Skin disorder—Cisplatin—esophageal cancer	0.000117	0.000998	CcSEcCtD
Everolimus—Eye disorder—Capecitabine—esophageal cancer	0.000117	0.000997	CcSEcCtD
Everolimus—Hyperhidrosis—Cisplatin—esophageal cancer	0.000117	0.000994	CcSEcCtD
Everolimus—Flushing—Capecitabine—esophageal cancer	0.000116	0.00099	CcSEcCtD
Everolimus—Cardiac disorder—Capecitabine—esophageal cancer	0.000116	0.00099	CcSEcCtD
Everolimus—Anorexia—Cisplatin—esophageal cancer	0.000115	0.00098	CcSEcCtD
Everolimus—Pancreatitis—Methotrexate—esophageal cancer	0.000114	0.000972	CcSEcCtD
Everolimus—Angiopathy—Capecitabine—esophageal cancer	0.000114	0.000967	CcSEcCtD
Everolimus—Immune system disorder—Capecitabine—esophageal cancer	0.000113	0.000963	CcSEcCtD
Everolimus—Mediastinal disorder—Capecitabine—esophageal cancer	0.000113	0.000961	CcSEcCtD
Everolimus—Hypotension—Cisplatin—esophageal cancer	0.000113	0.00096	CcSEcCtD
Everolimus—Chills—Capecitabine—esophageal cancer	0.000112	0.000957	CcSEcCtD
Everolimus—Alopecia—Capecitabine—esophageal cancer	0.000111	0.000942	CcSEcCtD
Everolimus—Pancytopenia—Methotrexate—esophageal cancer	0.000111	0.000942	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00011	0.000936	CcSEcCtD
Everolimus—Mental disorder—Capecitabine—esophageal cancer	0.00011	0.000934	CcSEcCtD
Everolimus—Malnutrition—Capecitabine—esophageal cancer	0.000109	0.000928	CcSEcCtD
Everolimus—Erythema—Capecitabine—esophageal cancer	0.000109	0.000928	CcSEcCtD
Everolimus—Dysuria—Methotrexate—esophageal cancer	0.000109	0.000927	CcSEcCtD
Everolimus—Neutropenia—Methotrexate—esophageal cancer	0.000109	0.000927	CcSEcCtD
Everolimus—Paraesthesia—Cisplatin—esophageal cancer	0.000108	0.000923	CcSEcCtD
Everolimus—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000108	0.000922	CcSEcCtD
Everolimus—Dyspnoea—Cisplatin—esophageal cancer	0.000108	0.000916	CcSEcCtD
Everolimus—Flatulence—Capecitabine—esophageal cancer	0.000107	0.000915	CcSEcCtD
Everolimus—Erectile dysfunction—Methotrexate—esophageal cancer	0.000107	0.000913	CcSEcCtD
Everolimus—Dysgeusia—Capecitabine—esophageal cancer	0.000107	0.000909	CcSEcCtD
Everolimus—Sirolimus—ABCB1—esophageal cancer	0.000106	0.0146	CrCbGaD
Everolimus—Tacrolimus—ABCB1—esophageal cancer	0.000106	0.0146	CrCbGaD
Everolimus—Back pain—Capecitabine—esophageal cancer	0.000105	0.000898	CcSEcCtD
Everolimus—Decreased appetite—Cisplatin—esophageal cancer	0.000105	0.000893	CcSEcCtD
Everolimus—Muscle spasms—Capecitabine—esophageal cancer	0.000105	0.000892	CcSEcCtD
Everolimus—Pneumonia—Methotrexate—esophageal cancer	0.000104	0.000889	CcSEcCtD
Everolimus—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000104	0.000887	CcSEcCtD
Everolimus—Infestation NOS—Methotrexate—esophageal cancer	0.000104	0.000884	CcSEcCtD
Everolimus—Infestation—Methotrexate—esophageal cancer	0.000104	0.000884	CcSEcCtD
Everolimus—Pain—Cisplatin—esophageal cancer	0.000103	0.000879	CcSEcCtD
Everolimus—Vision blurred—Capecitabine—esophageal cancer	0.000103	0.000875	CcSEcCtD
Everolimus—Tremor—Capecitabine—esophageal cancer	0.000102	0.00087	CcSEcCtD
Everolimus—Renal failure—Methotrexate—esophageal cancer	0.000102	0.000869	CcSEcCtD
Everolimus—Stomatitis—Methotrexate—esophageal cancer	0.000101	0.000862	CcSEcCtD
Everolimus—Ill-defined disorder—Capecitabine—esophageal cancer	0.000101	0.000861	CcSEcCtD
Everolimus—Conjunctivitis—Methotrexate—esophageal cancer	0.000101	0.00086	CcSEcCtD
Everolimus—Anaemia—Capecitabine—esophageal cancer	0.000101	0.000858	CcSEcCtD
Everolimus—Feeling abnormal—Cisplatin—esophageal cancer	9.94e-05	0.000847	CcSEcCtD
Everolimus—Haematuria—Methotrexate—esophageal cancer	9.9e-05	0.000843	CcSEcCtD
Everolimus—Malaise—Capecitabine—esophageal cancer	9.83e-05	0.000837	CcSEcCtD
Everolimus—Hepatobiliary disease—Methotrexate—esophageal cancer	9.82e-05	0.000836	CcSEcCtD
Everolimus—Epistaxis—Methotrexate—esophageal cancer	9.79e-05	0.000834	CcSEcCtD
Everolimus—Syncope—Capecitabine—esophageal cancer	9.77e-05	0.000832	CcSEcCtD
Everolimus—Leukopenia—Capecitabine—esophageal cancer	9.75e-05	0.000831	CcSEcCtD
Everolimus—Palpitations—Capecitabine—esophageal cancer	9.63e-05	0.00082	CcSEcCtD
Everolimus—Loss of consciousness—Capecitabine—esophageal cancer	9.58e-05	0.000816	CcSEcCtD
Everolimus—Body temperature increased—Cisplatin—esophageal cancer	9.54e-05	0.000812	CcSEcCtD
Everolimus—Cough—Capecitabine—esophageal cancer	9.51e-05	0.00081	CcSEcCtD
Everolimus—Hypertension—Capecitabine—esophageal cancer	9.41e-05	0.000801	CcSEcCtD
Everolimus—Haemoglobin—Methotrexate—esophageal cancer	9.37e-05	0.000798	CcSEcCtD
Everolimus—Haemorrhage—Methotrexate—esophageal cancer	9.32e-05	0.000794	CcSEcCtD
Everolimus—Hepatitis—Methotrexate—esophageal cancer	9.32e-05	0.000794	CcSEcCtD
Everolimus—Chest pain—Capecitabine—esophageal cancer	9.28e-05	0.00079	CcSEcCtD
Everolimus—Myalgia—Capecitabine—esophageal cancer	9.28e-05	0.00079	CcSEcCtD
Everolimus—Arthralgia—Capecitabine—esophageal cancer	9.28e-05	0.00079	CcSEcCtD
Everolimus—Pharyngitis—Methotrexate—esophageal cancer	9.25e-05	0.000788	CcSEcCtD
Everolimus—Anxiety—Capecitabine—esophageal cancer	9.25e-05	0.000788	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	9.21e-05	0.000785	CcSEcCtD
Everolimus—Urinary tract disorder—Methotrexate—esophageal cancer	9.2e-05	0.000784	CcSEcCtD
Everolimus—Discomfort—Capecitabine—esophageal cancer	9.17e-05	0.000781	CcSEcCtD
Everolimus—Urethral disorder—Methotrexate—esophageal cancer	9.13e-05	0.000778	CcSEcCtD
Everolimus—Dry mouth—Capecitabine—esophageal cancer	9.07e-05	0.000773	CcSEcCtD
Everolimus—Oedema—Capecitabine—esophageal cancer	8.89e-05	0.000758	CcSEcCtD
Everolimus—Hypersensitivity—Cisplatin—esophageal cancer	8.89e-05	0.000757	CcSEcCtD
Everolimus—Infection—Capecitabine—esophageal cancer	8.84e-05	0.000753	CcSEcCtD
Everolimus—Shock—Capecitabine—esophageal cancer	8.75e-05	0.000745	CcSEcCtD
Everolimus—Nervous system disorder—Capecitabine—esophageal cancer	8.72e-05	0.000743	CcSEcCtD
Everolimus—Eye disorder—Methotrexate—esophageal cancer	8.71e-05	0.000742	CcSEcCtD
Everolimus—Thrombocytopenia—Capecitabine—esophageal cancer	8.71e-05	0.000742	CcSEcCtD
Everolimus—Tachycardia—Capecitabine—esophageal cancer	8.68e-05	0.000739	CcSEcCtD
Everolimus—Asthenia—Cisplatin—esophageal cancer	8.66e-05	0.000737	CcSEcCtD
Everolimus—Cardiac disorder—Methotrexate—esophageal cancer	8.65e-05	0.000737	CcSEcCtD
Everolimus—Skin disorder—Capecitabine—esophageal cancer	8.64e-05	0.000736	CcSEcCtD
Everolimus—Hyperhidrosis—Capecitabine—esophageal cancer	8.6e-05	0.000732	CcSEcCtD
Everolimus—Anorexia—Capecitabine—esophageal cancer	8.48e-05	0.000722	CcSEcCtD
Everolimus—Angiopathy—Methotrexate—esophageal cancer	8.45e-05	0.00072	CcSEcCtD
Everolimus—Immune system disorder—Methotrexate—esophageal cancer	8.42e-05	0.000717	CcSEcCtD
Everolimus—Mediastinal disorder—Methotrexate—esophageal cancer	8.4e-05	0.000715	CcSEcCtD
Everolimus—Chills—Methotrexate—esophageal cancer	8.36e-05	0.000712	CcSEcCtD
Everolimus—Hypotension—Capecitabine—esophageal cancer	8.31e-05	0.000708	CcSEcCtD
Everolimus—Diarrhoea—Cisplatin—esophageal cancer	8.25e-05	0.000703	CcSEcCtD
Everolimus—Alopecia—Methotrexate—esophageal cancer	8.23e-05	0.000701	CcSEcCtD
Everolimus—Mental disorder—Methotrexate—esophageal cancer	8.16e-05	0.000695	CcSEcCtD
Everolimus—Malnutrition—Methotrexate—esophageal cancer	8.11e-05	0.000691	CcSEcCtD
Everolimus—Erythema—Methotrexate—esophageal cancer	8.11e-05	0.000691	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Capecitabine—esophageal cancer	8.1e-05	0.00069	CcSEcCtD
Everolimus—Insomnia—Capecitabine—esophageal cancer	8.04e-05	0.000685	CcSEcCtD
Everolimus—Paraesthesia—Capecitabine—esophageal cancer	7.99e-05	0.00068	CcSEcCtD
Everolimus—Dysgeusia—Methotrexate—esophageal cancer	7.94e-05	0.000677	CcSEcCtD
Everolimus—Dyspnoea—Capecitabine—esophageal cancer	7.93e-05	0.000675	CcSEcCtD
Everolimus—Back pain—Methotrexate—esophageal cancer	7.85e-05	0.000668	CcSEcCtD
Everolimus—Dyspepsia—Capecitabine—esophageal cancer	7.83e-05	0.000667	CcSEcCtD
Everolimus—Decreased appetite—Capecitabine—esophageal cancer	7.73e-05	0.000659	CcSEcCtD
Everolimus—Gastrointestinal disorder—Capecitabine—esophageal cancer	7.68e-05	0.000654	CcSEcCtD
Everolimus—Vomiting—Cisplatin—esophageal cancer	7.67e-05	0.000653	CcSEcCtD
Everolimus—Fatigue—Capecitabine—esophageal cancer	7.67e-05	0.000653	CcSEcCtD
Everolimus—Vision blurred—Methotrexate—esophageal cancer	7.65e-05	0.000651	CcSEcCtD
Everolimus—Rash—Cisplatin—esophageal cancer	7.61e-05	0.000648	CcSEcCtD
Everolimus—Pain—Capecitabine—esophageal cancer	7.61e-05	0.000648	CcSEcCtD
Everolimus—Constipation—Capecitabine—esophageal cancer	7.61e-05	0.000648	CcSEcCtD
Everolimus—Dermatitis—Cisplatin—esophageal cancer	7.6e-05	0.000647	CcSEcCtD
Everolimus—Ill-defined disorder—Methotrexate—esophageal cancer	7.53e-05	0.000641	CcSEcCtD
Everolimus—Anaemia—Methotrexate—esophageal cancer	7.5e-05	0.000639	CcSEcCtD
Everolimus—Feeling abnormal—Capecitabine—esophageal cancer	7.33e-05	0.000624	CcSEcCtD
Everolimus—Malaise—Methotrexate—esophageal cancer	7.32e-05	0.000623	CcSEcCtD
Everolimus—Gastrointestinal pain—Capecitabine—esophageal cancer	7.27e-05	0.000619	CcSEcCtD
Everolimus—Leukopenia—Methotrexate—esophageal cancer	7.26e-05	0.000619	CcSEcCtD
Everolimus—Nausea—Cisplatin—esophageal cancer	7.17e-05	0.00061	CcSEcCtD
Everolimus—Cough—Methotrexate—esophageal cancer	7.08e-05	0.000603	CcSEcCtD
Everolimus—Abdominal pain—Capecitabine—esophageal cancer	7.03e-05	0.000599	CcSEcCtD
Everolimus—Body temperature increased—Capecitabine—esophageal cancer	7.03e-05	0.000599	CcSEcCtD
Everolimus—Convulsion—Methotrexate—esophageal cancer	7.03e-05	0.000599	CcSEcCtD
Everolimus—Myalgia—Methotrexate—esophageal cancer	6.91e-05	0.000588	CcSEcCtD
Everolimus—Chest pain—Methotrexate—esophageal cancer	6.91e-05	0.000588	CcSEcCtD
Everolimus—Arthralgia—Methotrexate—esophageal cancer	6.91e-05	0.000588	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	6.86e-05	0.000584	CcSEcCtD
Everolimus—Discomfort—Methotrexate—esophageal cancer	6.82e-05	0.000581	CcSEcCtD
Everolimus—Infection—Methotrexate—esophageal cancer	6.58e-05	0.00056	CcSEcCtD
Everolimus—Hypersensitivity—Capecitabine—esophageal cancer	6.55e-05	0.000558	CcSEcCtD
Everolimus—Nervous system disorder—Methotrexate—esophageal cancer	6.49e-05	0.000553	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—esophageal cancer	6.48e-05	0.000552	CcSEcCtD
Everolimus—Skin disorder—Methotrexate—esophageal cancer	6.43e-05	0.000548	CcSEcCtD
Everolimus—Hyperhidrosis—Methotrexate—esophageal cancer	6.4e-05	0.000545	CcSEcCtD
Everolimus—Asthenia—Capecitabine—esophageal cancer	6.38e-05	0.000544	CcSEcCtD
Everolimus—Anorexia—Methotrexate—esophageal cancer	6.31e-05	0.000538	CcSEcCtD
Everolimus—Pruritus—Capecitabine—esophageal cancer	6.29e-05	0.000536	CcSEcCtD
Everolimus—Hypotension—Methotrexate—esophageal cancer	6.19e-05	0.000527	CcSEcCtD
Everolimus—Diarrhoea—Capecitabine—esophageal cancer	6.08e-05	0.000518	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methotrexate—esophageal cancer	6.03e-05	0.000514	CcSEcCtD
Everolimus—Insomnia—Methotrexate—esophageal cancer	5.99e-05	0.00051	CcSEcCtD
Everolimus—Paraesthesia—Methotrexate—esophageal cancer	5.94e-05	0.000506	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—esophageal cancer	5.9e-05	0.000503	CcSEcCtD
Everolimus—Somnolence—Methotrexate—esophageal cancer	5.89e-05	0.000501	CcSEcCtD
Everolimus—Dizziness—Capecitabine—esophageal cancer	5.88e-05	0.000501	CcSEcCtD
Everolimus—Dyspepsia—Methotrexate—esophageal cancer	5.83e-05	0.000496	CcSEcCtD
Everolimus—Decreased appetite—Methotrexate—esophageal cancer	5.76e-05	0.00049	CcSEcCtD
Everolimus—Gastrointestinal disorder—Methotrexate—esophageal cancer	5.72e-05	0.000487	CcSEcCtD
Everolimus—Fatigue—Methotrexate—esophageal cancer	5.71e-05	0.000486	CcSEcCtD
Everolimus—Pain—Methotrexate—esophageal cancer	5.66e-05	0.000482	CcSEcCtD
Everolimus—Vomiting—Capecitabine—esophageal cancer	5.65e-05	0.000482	CcSEcCtD
Everolimus—Rash—Capecitabine—esophageal cancer	5.61e-05	0.000478	CcSEcCtD
Everolimus—Dermatitis—Capecitabine—esophageal cancer	5.6e-05	0.000477	CcSEcCtD
Everolimus—Headache—Capecitabine—esophageal cancer	5.57e-05	0.000475	CcSEcCtD
Everolimus—FKBP1A—Disease—CALR—esophageal cancer	5.5e-05	0.000697	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CDKN1A—esophageal cancer	5.5e-05	0.000697	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KMT2D—esophageal cancer	5.49e-05	0.000696	CbGpPWpGaD
Everolimus—MTOR—Disease—CSNK1A1—esophageal cancer	5.49e-05	0.000695	CbGpPWpGaD
Everolimus—Feeling abnormal—Methotrexate—esophageal cancer	5.46e-05	0.000465	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—esophageal cancer	5.44e-05	0.000689	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—esophageal cancer	5.43e-05	0.000688	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Methotrexate—esophageal cancer	5.41e-05	0.000461	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—FBXW7—esophageal cancer	5.35e-05	0.000678	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CREBBP—esophageal cancer	5.32e-05	0.000675	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FBXW7—esophageal cancer	5.32e-05	0.000675	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HMGB1—esophageal cancer	5.32e-05	0.000674	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—RB1—esophageal cancer	5.3e-05	0.000672	CbGpPWpGaD
Everolimus—Nausea—Capecitabine—esophageal cancer	5.28e-05	0.00045	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CDKN1A—esophageal cancer	5.25e-05	0.000665	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—CDKN1A—esophageal cancer	5.25e-05	0.000665	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—CDKN1A—esophageal cancer	5.25e-05	0.000665	CbGpPWpGaD
Everolimus—Body temperature increased—Methotrexate—esophageal cancer	5.23e-05	0.000446	CcSEcCtD
Everolimus—Abdominal pain—Methotrexate—esophageal cancer	5.23e-05	0.000446	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—PIK3CA—esophageal cancer	5.21e-05	0.000661	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—CDKN1A—esophageal cancer	5.2e-05	0.000659	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—PIK3CA—esophageal cancer	5.18e-05	0.000656	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HIST1H2BM—esophageal cancer	5.18e-05	0.000656	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—CDKN1A—esophageal cancer	5.15e-05	0.000653	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—CDKN1A—esophageal cancer	5.13e-05	0.00065	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PDE4D—esophageal cancer	5.13e-05	0.00065	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—esophageal cancer	5.1e-05	0.000647	CbGpPWpGaD
Everolimus—MTOR—Immune System—ELMO1—esophageal cancer	4.99e-05	0.000633	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MYC—esophageal cancer	4.94e-05	0.000626	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADCYAP1—esophageal cancer	4.9e-05	0.00062	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—esophageal cancer	4.88e-05	0.000619	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GNG7—esophageal cancer	4.88e-05	0.000618	CbGpPWpGaD
Everolimus—Hypersensitivity—Methotrexate—esophageal cancer	4.88e-05	0.000416	CcSEcCtD
Everolimus—MTOR—B Cell Activation—CDKN1A—esophageal cancer	4.86e-05	0.000615	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—esophageal cancer	4.83e-05	0.000612	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—EGFR—esophageal cancer	4.81e-05	0.000609	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	4.77e-05	0.000605	CbGpPWpGaD
Everolimus—Asthenia—Methotrexate—esophageal cancer	4.75e-05	0.000405	CcSEcCtD
Everolimus—Pruritus—Methotrexate—esophageal cancer	4.68e-05	0.000399	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CDKN2A—esophageal cancer	4.66e-05	0.000591	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1A—esophageal cancer	4.65e-05	0.000589	CbGpPWpGaD
Everolimus—MTOR—Disease—ELMO1—esophageal cancer	4.61e-05	0.000584	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—EGFR—esophageal cancer	4.59e-05	0.000582	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—XIAP—esophageal cancer	4.57e-05	0.00058	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—esophageal cancer	4.57e-05	0.000579	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—esophageal cancer	4.57e-05	0.000579	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—EGFR—esophageal cancer	4.55e-05	0.000576	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	4.54e-05	0.000575	CbGpPWpGaD
Everolimus—Diarrhoea—Methotrexate—esophageal cancer	4.53e-05	0.000386	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—EGFR—esophageal cancer	4.52e-05	0.000573	CbGpPWpGaD
Everolimus—MTOR—Disease—TPI1—esophageal cancer	4.5e-05	0.000571	CbGpPWpGaD
Everolimus—MTOR—Disease—GSTO1—esophageal cancer	4.5e-05	0.000571	CbGpPWpGaD
Everolimus—MTOR—Immune System—CFL1—esophageal cancer	4.5e-05	0.000571	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	4.48e-05	0.000568	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—WWOX—esophageal cancer	4.48e-05	0.000567	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—esophageal cancer	4.46e-05	0.000565	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—PIK3CA—esophageal cancer	4.43e-05	0.000561	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ABL1—esophageal cancer	4.4e-05	0.000558	CbGpPWpGaD
Everolimus—Dizziness—Methotrexate—esophageal cancer	4.38e-05	0.000373	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CTNNA1—esophageal cancer	4.32e-05	0.000548	CbGpPWpGaD
Everolimus—MTOR—Disease—ALDOB—esophageal cancer	4.32e-05	0.000547	CbGpPWpGaD
Everolimus—MTOR—Immune System—LGALS3—esophageal cancer	4.31e-05	0.000547	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFBR2—esophageal cancer	4.3e-05	0.000546	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL2—esophageal cancer	4.3e-05	0.000545	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FKBP1A—esophageal cancer	4.26e-05	0.00054	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—esophageal cancer	4.26e-05	0.000539	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—esophageal cancer	4.26e-05	0.000539	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—EGFR—esophageal cancer	4.26e-05	0.000539	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	4.25e-05	0.000539	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—PIK3CA—esophageal cancer	4.24e-05	0.000537	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—EGFR—esophageal cancer	4.22e-05	0.000535	CbGpPWpGaD
Everolimus—Vomiting—Methotrexate—esophageal cancer	4.21e-05	0.000359	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—ERBB2—esophageal cancer	4.18e-05	0.00053	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—esophageal cancer	4.18e-05	0.00053	CbGpPWpGaD
Everolimus—Rash—Methotrexate—esophageal cancer	4.17e-05	0.000356	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—PIK3CA—esophageal cancer	4.17e-05	0.000529	CbGpPWpGaD
Everolimus—Dermatitis—Methotrexate—esophageal cancer	4.17e-05	0.000355	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—WIF1—esophageal cancer	4.16e-05	0.000528	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—EGFR—esophageal cancer	4.16e-05	0.000527	CbGpPWpGaD
Everolimus—MTOR—Disease—GAPDH—esophageal cancer	4.16e-05	0.000527	CbGpPWpGaD
Everolimus—MTOR—Disease—HIST1H2BM—esophageal cancer	4.16e-05	0.000527	CbGpPWpGaD
Everolimus—Headache—Methotrexate—esophageal cancer	4.15e-05	0.000353	CcSEcCtD
Everolimus—FKBP1A—Disease—SMAD4—esophageal cancer	4.07e-05	0.000516	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—esophageal cancer	4.06e-05	0.000514	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PSME2—esophageal cancer	4.02e-05	0.000509	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PSME1—esophageal cancer	4.02e-05	0.000509	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—PIK3CA—esophageal cancer	4e-05	0.000507	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ANXA1—esophageal cancer	4e-05	0.000507	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—PIK3CA—esophageal cancer	3.98e-05	0.000505	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—PIK3CA—esophageal cancer	3.96e-05	0.000502	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—PIK3CA—esophageal cancer	3.94e-05	0.0005	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—EGFR—esophageal cancer	3.94e-05	0.000499	CbGpPWpGaD
Everolimus—Nausea—Methotrexate—esophageal cancer	3.93e-05	0.000335	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—PIK3CA—esophageal cancer	3.93e-05	0.000498	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SST—esophageal cancer	3.89e-05	0.000493	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—esophageal cancer	3.87e-05	0.00049	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CSNK1A1—esophageal cancer	3.84e-05	0.000487	CbGpPWpGaD
Everolimus—MTOR—Immune System—ACTB—esophageal cancer	3.83e-05	0.000485	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN1A—esophageal cancer	3.81e-05	0.000483	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOTCH3—esophageal cancer	3.79e-05	0.00048	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GHRL—esophageal cancer	3.79e-05	0.00048	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—esophageal cancer	3.77e-05	0.000478	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTPN2—esophageal cancer	3.74e-05	0.000474	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FBXW7—esophageal cancer	3.73e-05	0.000472	CbGpPWpGaD
Everolimus—MTOR—Immune System—B2M—esophageal cancer	3.7e-05	0.000469	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—PIK3CA—esophageal cancer	3.69e-05	0.000468	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—PIK3CA—esophageal cancer	3.69e-05	0.000468	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PIK3CA—esophageal cancer	3.69e-05	0.000468	CbGpPWpGaD
Everolimus—MTOR—Disease—XIAP—esophageal cancer	3.67e-05	0.000465	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—PIK3CA—esophageal cancer	3.66e-05	0.000464	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—PIK3CA—esophageal cancer	3.63e-05	0.00046	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—EP300—esophageal cancer	3.63e-05	0.00046	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	3.61e-05	0.000458	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—PIK3CA—esophageal cancer	3.61e-05	0.000458	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PFN1—esophageal cancer	3.59e-05	0.000455	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CDKN1A—esophageal cancer	3.57e-05	0.000453	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	3.57e-05	0.000452	CbGpPWpGaD
Everolimus—MTOR—Immune System—PSME2—esophageal cancer	3.49e-05	0.000443	CbGpPWpGaD
Everolimus—MTOR—Immune System—PSME1—esophageal cancer	3.49e-05	0.000443	CbGpPWpGaD
Everolimus—MTOR—Immune System—HSPA5—esophageal cancer	3.46e-05	0.000439	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—PIK3CA—esophageal cancer	3.42e-05	0.000433	CbGpPWpGaD
Everolimus—MTOR—Disease—B2M—esophageal cancer	3.41e-05	0.000433	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	3.4e-05	0.000431	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOTCH2—esophageal cancer	3.4e-05	0.000431	CbGpPWpGaD
Everolimus—MTOR—Immune System—CALR—esophageal cancer	3.35e-05	0.000425	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	3.35e-05	0.000425	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR4—esophageal cancer	3.33e-05	0.000423	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HIF1A—esophageal cancer	3.33e-05	0.000423	CbGpPWpGaD
Everolimus—MTOR—Disease—ENO1—esophageal cancer	3.27e-05	0.000415	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—esophageal cancer	3.27e-05	0.000415	CbGpPWpGaD
Everolimus—MTOR—Immune System—FBXW7—esophageal cancer	3.24e-05	0.000411	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ELMO1—esophageal cancer	3.23e-05	0.000409	CbGpPWpGaD
Everolimus—MTOR—Disease—PSME1—esophageal cancer	3.23e-05	0.000409	CbGpPWpGaD
Everolimus—MTOR—Disease—PSME2—esophageal cancer	3.23e-05	0.000409	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKAP13—esophageal cancer	3.15e-05	0.0004	CbGpPWpGaD
Everolimus—MTOR—Immune System—HMGB1—esophageal cancer	3.1e-05	0.000393	CbGpPWpGaD
Everolimus—MTOR—Disease—CALR—esophageal cancer	3.1e-05	0.000392	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS2—esophageal cancer	3.03e-05	0.000384	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFBR2—esophageal cancer	3.01e-05	0.000382	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOTCH1—esophageal cancer	3e-05	0.000381	CbGpPWpGaD
Everolimus—MTOR—Disease—FBXW7—esophageal cancer	2.99e-05	0.000379	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HIST1H2BM—esophageal cancer	2.91e-05	0.000369	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—EGFR—esophageal cancer	2.9e-05	0.000367	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDE4D—esophageal cancer	2.89e-05	0.000366	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CASP8—esophageal cancer	2.86e-05	0.000363	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SMAD4—esophageal cancer	2.85e-05	0.000362	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CREBBP—esophageal cancer	2.85e-05	0.000361	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GNG7—esophageal cancer	2.74e-05	0.000348	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CREBBP—esophageal cancer	2.72e-05	0.000345	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—esophageal cancer	2.59e-05	0.000329	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—XIAP—esophageal cancer	2.57e-05	0.000326	CbGpPWpGaD
Everolimus—MTOR—Immune System—ABL1—esophageal cancer	2.56e-05	0.000325	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PIK3CA—esophageal cancer	2.52e-05	0.000319	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—BCL2—esophageal cancer	2.46e-05	0.000311	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS3—esophageal cancer	2.44e-05	0.000309	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNA1—esophageal cancer	2.43e-05	0.000308	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFBR2—esophageal cancer	2.42e-05	0.000307	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL2—esophageal cancer	2.42e-05	0.000306	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ERBB2—esophageal cancer	2.39e-05	0.000302	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HIF1A—esophageal cancer	2.33e-05	0.000296	CbGpPWpGaD
Everolimus—MTOR—Disease—SMAD4—esophageal cancer	2.29e-05	0.00029	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB2—esophageal cancer	2.29e-05	0.00029	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB2—esophageal cancer	2.28e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PSME1—esophageal cancer	2.26e-05	0.000286	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PSME2—esophageal cancer	2.26e-05	0.000286	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ANXA1—esophageal cancer	2.25e-05	0.000285	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KDR—esophageal cancer	2.23e-05	0.000283	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—esophageal cancer	2.23e-05	0.000283	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SST—esophageal cancer	2.19e-05	0.000277	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GHRL—esophageal cancer	2.13e-05	0.00027	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH3—esophageal cancer	2.13e-05	0.00027	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOTCH1—esophageal cancer	2.1e-05	0.000267	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FBXW7—esophageal cancer	2.1e-05	0.000266	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1A—esophageal cancer	2.04e-05	0.000258	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1A—esophageal cancer	1.96e-05	0.000248	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1A—esophageal cancer	1.95e-05	0.000247	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR4—esophageal cancer	1.94e-05	0.000246	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EP300—esophageal cancer	1.94e-05	0.000246	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH2—esophageal cancer	1.91e-05	0.000242	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CREBBP—esophageal cancer	1.91e-05	0.000242	CbGpPWpGaD
Everolimus—MTOR—Disease—HIF1A—esophageal cancer	1.88e-05	0.000238	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EP300—esophageal cancer	1.85e-05	0.000235	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.83e-05	0.000231	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.83e-05	0.000231	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—esophageal cancer	1.71e-05	0.000216	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—esophageal cancer	1.71e-05	0.000216	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFBR2—esophageal cancer	1.7e-05	0.000215	CbGpPWpGaD
Everolimus—MTOR—Disease—NOTCH1—esophageal cancer	1.69e-05	0.000214	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP8—esophageal cancer	1.67e-05	0.000211	CbGpPWpGaD
Everolimus—MTOR—Immune System—CREBBP—esophageal cancer	1.66e-05	0.00021	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—esophageal cancer	1.65e-05	0.00021	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—esophageal cancer	1.62e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMAD4—esophageal cancer	1.6e-05	0.000203	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—esophageal cancer	1.6e-05	0.000202	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—esophageal cancer	1.59e-05	0.000201	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—esophageal cancer	1.58e-05	0.0002	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.55e-05	0.000197	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA1—esophageal cancer	1.55e-05	0.000197	CbGpPWpGaD
Everolimus—MTOR—Disease—CREBBP—esophageal cancer	1.53e-05	0.000194	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—esophageal cancer	1.43e-05	0.000182	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—esophageal cancer	1.43e-05	0.000181	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA2—esophageal cancer	1.42e-05	0.00018	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—esophageal cancer	1.41e-05	0.000179	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—esophageal cancer	1.39e-05	0.000176	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—esophageal cancer	1.38e-05	0.000175	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—esophageal cancer	1.37e-05	0.000174	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—esophageal cancer	1.37e-05	0.000174	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1A—esophageal cancer	1.37e-05	0.000173	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADH7—esophageal cancer	1.32e-05	0.000167	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.32e-05	0.000167	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HIF1A—esophageal cancer	1.31e-05	0.000166	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EP300—esophageal cancer	1.3e-05	0.000165	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB2—esophageal cancer	1.28e-05	0.000163	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KDR—esophageal cancer	1.26e-05	0.000159	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—esophageal cancer	1.25e-05	0.000159	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1A—esophageal cancer	1.19e-05	0.00015	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH1—esophageal cancer	1.18e-05	0.00015	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.16e-05	0.000147	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—esophageal cancer	1.13e-05	0.000143	CbGpPWpGaD
Everolimus—MTOR—Immune System—EP300—esophageal cancer	1.13e-05	0.000143	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—esophageal cancer	1.11e-05	0.00014	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMP—esophageal cancer	1.11e-05	0.00014	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1A—esophageal cancer	1.1e-05	0.000139	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.08e-05	0.000136	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CREBBP—esophageal cancer	1.07e-05	0.000136	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.05e-05	0.000133	CbGpPWpGaD
Everolimus—MTOR—Disease—EP300—esophageal cancer	1.04e-05	0.000132	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTO1—esophageal cancer	1e-05	0.000127	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TPI1—esophageal cancer	1e-05	0.000127	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—esophageal cancer	9.63e-06	0.000122	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—esophageal cancer	9.61e-06	0.000122	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—esophageal cancer	9.6e-06	0.000122	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDOB—esophageal cancer	9.59e-06	0.000122	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—esophageal cancer	9.3e-06	0.000118	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GAPDH—esophageal cancer	9.23e-06	0.000117	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CRABP1—esophageal cancer	9.15e-06	0.000116	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—esophageal cancer	9.09e-06	0.000115	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—esophageal cancer	8.98e-06	0.000114	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—esophageal cancer	8.89e-06	0.000113	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNG7—esophageal cancer	8.7e-06	0.00011	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—esophageal cancer	8.36e-06	0.000106	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDH2—esophageal cancer	8.16e-06	0.000103	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—esophageal cancer	7.94e-06	0.000101	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTT1—esophageal cancer	7.76e-06	9.83e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—esophageal cancer	7.72e-06	9.78e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1A—esophageal cancer	7.68e-06	9.73e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2A6—esophageal cancer	7.67e-06	9.72e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EP300—esophageal cancer	7.3e-06	9.26e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO1—esophageal cancer	7.27e-06	9.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS1—esophageal cancer	7.27e-06	9.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PSME2—esophageal cancer	7.16e-06	9.08e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PSME1—esophageal cancer	7.16e-06	9.08e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—esophageal cancer	6.37e-06	8.07e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—esophageal cancer	6.23e-06	7.89e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1B1—esophageal cancer	6.18e-06	7.84e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP19A1—esophageal cancer	5.81e-06	7.37e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—esophageal cancer	5.4e-06	6.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.3e-06	6.72e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—esophageal cancer	5.23e-06	6.63e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.09e-06	6.45e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.4e-06	4.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—esophageal cancer	3.05e-06	3.86e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.79e-06	3.53e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—EP300—esophageal cancer	2.32e-06	2.94e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.71e-06	2.17e-05	CbGpPWpGaD
